{
    "nctId": "NCT00006228",
    "briefTitle": "Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Anti-HER-2 Monoclonal Antibody Trastuzumab (Herceptin) in Combination With Low Dose Interleukin-2 (Proleukin) in Metastatic Breast Cancer Patients Who Have Previously Failed Trastuzumab",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "Response rate using Response Evaluation Criteria in Solid Tumors (RECIST)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Primary and/or metastatic disease\n* HER2 overexpression 3+ by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH)\n\n  * Tumors with HER2 2+ overexpression by IHC allowed if confirmed by FISH\n* Progressive disease during or within 12 months of receiving prior regimen containing trastuzumab (Herceptin)\n* Unidimensionally measurable disease\n\n  * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan\n  * The following are not considered measurable:\n\n    * Bone metastases\n    * Pleural or peritoneal effusion\n    * Ascites\n    * Leptomeningeal disease\n    * Lymphangitic disease\n    * Inflammatory breast cancer\n    * Cystic lesions\n    * CNS lesions\n* CNS metastases allowed if all of the following conditions are met:\n\n  * Asymptomatic\n  * At least 3 months since prior surgery and/or cranial irradiation\n  * At least 3 weeks since prior steroids\n* Hormone receptor status:\n\n  * Not specified\n* Male or female\n* Performance status - ECOG 0-2\n* Granulocyte count at least 1,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* SGOT and SGPT no greater than 2 times ULN (5 times ULN for liver metastases)\n* Alkaline phosphatase no greater than 2 times ULN (5 times ULN for liver metastases)\n* Creatinine no greater than 1.5 times ULN\n* LVEF at least lower limit of normal by MUGA or echocardiogram\n* No congestive heart failure or active ischemic heart disease\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No psychiatric illness, medical condition, or uncontrolled infection that would preclude study\n* No underlying immunodeficiency (e.g., HIV or autoimmune disease)\n* No other prior malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix\n* See Disease Characteristics\n* Prior cumulative doxorubicin dose no greater than 360 mg/m\\^2\n* At least 3 weeks since prior chemotherapy\n* No more than 2 prior chemotherapy regimens for metastatic disease\n* No concurrent chemotherapy\n* See Disease Characteristics\n* At least 3 weeks since prior endocrine therapy\n* No concurrent corticosteroids or dexamethasone\n* Concurrent hormones allowed for conditions unrelated to disease (e.g., insulin for diabetes)\n* See Disease Characteristics\n* At least 3 weeks since prior radiotherapy\n* No prior radiotherapy to study lesion, unless evidence of disease progression\n* No concurrent palliative radiotherapy\n* See Disease Characteristics\n* At least 4 weeks since prior major surgery\n* No concurrent immunosuppressive drugs",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}